Sarepta's shares sink as second Elevidys-linked death triggers safety concerns, dosing halts and trial pauses.

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares plunged almost 45% after the company disclosed the death of a second patient from acute liver failure linked with its experimental gene therapy Elevidys for Duchenne muscular dystrophy (DMD). In response, the company is convening an independent expert panel to evaluate and develop an enhanced immunosuppressive regimen, including sirolimus, to reduce the risk of acute liver failure in non-ambulatory DMD patients treated with Elevidys, with any new protocol subject to Food and Drug Administration (FDA) review and approval.

MAIN remains a top BDC pick in my portfolio, but after a 10%+ rally, I rate it a hold. MAIN's internally managed structure and disciplined expense control set it apart, supporting long-term shareholder value. The portfolio's mix of fixed-rate debt, interest rate floors, and equity positions makes MAIN resilient to interest rate cuts.

MP Materials Corp. is the only fully integrated U.S. rare earth producer, positioned to benefit from rising demand and U.S. supply chain security initiatives. Recent geopolitical tensions and Chinese export restrictions highlight the critical need for domestic rare earth supply, strengthening MP's strategic value. Despite near-term losses from ramping up operations, MP's vertical integration, government support, and potential tax credits set the stage for strong future growth.

MIR, ASM and PWR outperform the S&P 500 after Zacks upgrades, spotlighting key stock picks in a volatile market.

Celsius remains a buy thanks to strong improvements, a healthy balance sheet, and high-potential international expansion, despite recent growth slowdowns. The Alani acquisition adds a second high-growth brand, boosting sector potential and positioning Celsius for leadership in the better-for-you energy drink market and beyond. Valuation scenarios show attractive risk-reward, with significant upside if international and Alani growth materialize, and limited downside due to acquisition appeal.

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN). “Too many people living with lupus face delays in diagnosis and disconnects in care,” said Court Horncastle, Senior Vice President at GSK. “With this initiative, we're proud to support the organizations working within local communities to improve.

QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.

HOLX lifts margins despite tariffs and weak China sales, leaning on diagnostics strength and high-margin buys.

NFG lifts its dividend for the 55th straight year as shale growth and pipeline upgrades fuel long-term strength.

Jack Henry & Associates, a financial technology company that provides a range of services to various financial firms, is now a $13 billion (by market cap) fintech player. JKHY increased its dividend for 35 consecutive years, with a 10-year dividend growth rate of 9.6%. JKHY grew its revenue from $1.3 billion in FY 2015 to $2.2 billion in FY 2024, a compound annual growth rate of 6%.

PHILADELPHIA, June 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Barrack, Rodos & Bacine reminds investors who purchased stock in Compass Group Diversified Holdings, LLC (NYSE: CODI) between May 1, 2024, and May 7, 2025 have less than one month to seek appointment as lead plaintiff in a pending action against Compass. Compass is an investment holding company and one of its subsidiary businesses is Lugano Holdings, Inc., a jewelry company.

Boeing stock has strongly outperformed the S&P 500 in 2024, driven by robust airplane orders and improving production stability. May saw a major order surge, highlighted by Qatar Airways and unidentified customers, bringing net orders to 300 aircraft worth $32.5 billion. Deliveries remain stable above 40 planes per month, with year-to-date deliveries and values significantly higher than last year.

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- SoFi, a leading provider of thematic and income ETFs, today announced monthly distributions on the SoFi Enhanced Yield ETF (THTA). Distribution as of 06/16/2025 ETF Ticker Distribution per Share Distribution Rate * 30-DaySEC Yield** Ex-Date Record Date Payment Date THTA $0.1504 12.00% 4.18% 06/17/2025 06/17/2025 06/18/2025 Inception date: 11/15/2023 Click here to view standardized performance for THTA.

Company Announcement COPENHAGEN, Denmark; June 16, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.

Canadian Natural Resources offers a massive, low-cost reserve base, low maintenance capital needs, and strong shareholder returns. Despite not trading at a valuation multiple discount, my DCF model supports a fair value of US$47.38 per share. Key risks include exposure to Canadian oil price discounts, asset concentration, and potential regulatory changes.

GLDD's fleet overhaul and infrastructure boom lift Q1 margins to 24.7%, boosting investor appeal with discounted valuation.

MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.

AppLovin's stock surged 53% since April, outperforming the S&P 500's 13% gain, driven by ad-tech focus. The Axon platform processed 1B+ daily users, delivering 71% YoY ad revenue growth to $1.16 billion in Q1-FY25. Advertising EBITDA margin reached 81%, with $943 million adjusted EBITDA, supported by Axon 2 and reinforcement learning gains.

Key Points in This Article: Growing a $100,000 investment into a $1 million retirement portfolio in 10 years requires a 25.9% CAGR from high-growth stocks with solid financials.